Source comparison
Tesamorelin + Ipamorelin Blend: Dosing Comparison by Protocol Type
Standard 40s Protocol 300mcg 200mcg Once daily (pre-bed) 5 days on, 2 days off Visceral fat reduction, IGF-1 normalisation Optimal balance of efficacy and tolerability for age group. Lower tesamorelin dose prevents joint issues while ipamorelin maintains GH pu
This comparison does not assign a generated winner or score.
- Standard 40s Protocol
- 300mcg
- 200mcg
- Once daily (pre-bed)
- 5 days on, 2 days off
- Visceral fat reduction, IGF-1 normalisation
- Optimal balance of efficacy and tolerability for age group. Lower tesamorelin dose prevents joint issues while ipamorelin maintains GH pulse amplitude
- High-Dose Monotherapy
- 1–2mg
- 0mcg
- Once daily
- Continuous
- Maximum visceral fat reduction
- Higher side effect burden (joint stiffness, oedema) with marginal additional fat loss. Hepatic IGF-1 conversion saturates beyond 500mcg in 40+ demographic
- Ipamorelin-Only Protocol
- 300–500mcg
- 2–3x daily
- General GH restoration
- Misses tesamorelin's targeted visceral adipose receptor action. Effective for muscle preservation but weaker visceral fat mobilisation in metabolically resistant tissue
- Pulse-Focused Protocol
- Twice daily (morning + pre-bed)
- Maximum IGF-1 elevation
- More complex dosing with limited additional benefit. Single pre-bed dose captures nocturnal GH peak when lipolytic conditions are optimal